Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Meghan Jude Mooradian, M.D.

Title
Institution
Department
Address
Phone

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M, Reynolds KL. Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. Curr Oncol Rep. 2020 Mar 21; 22(4):39. PMID: 32200442.
    Citations:    
  2. Dubey D, David WS, Reynolds KL, Chute DF, Clement NF, Cohen JV, Lawrence DP, Mooradian MJ, Sullivan RJ, Guidon AC. Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. Ann Neurol. 2020 May; 87(5):659-669. PMID: 32086972.
    Citations:    
  3. Gainor JF, Rizvi H, Jimenez Aguilar E, Skoulidis F, Yeap BY, Naidoo J, Khosrowjerdi S, Mooradian M, Lydon C, Illei P, Zhang J, Peterson R, Ricciuti B, Nishino M, Zhang J, Roth JA, Grishman J, Anderson D, Little BP, Carter BW, Arbour K, Sauter JL, Mino-Kenudson M, Heymach JV, Digumarthy S, Shaw AT, Awad MM, Hellmann MD. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression =50. Ann Oncol. 2020 Mar; 31(3):404-411. PMID: 32067682.
    Citations:    
  4. Zubiri L, Allen IM, Taylor MS, Guidon AC, Chen ST, Schoenfeld SR, Neilan TG, Sise ME, Mooradian MJ, Rubin KM, Leaf RK, Parikh AR, Faje A, Gainor JF, Cohen JV, Fintelmann FJ, Kohler MJ, Dougan M, Reynolds KL. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2020 Mar; 25(3):e398-e404. PMID: 32162817.
    Citations:    
  5. Zubiri L, Allen IM, Taylor MS, Guidon AC, Chen ST, Schoenfeld SR, Neilan TG, Sise ME, Mooradian MJ, Rubin KM, Leaf RK, Parikh AR, Faje A, Gainor JF, Cohen JV, Fintelmann FJ, Kohler MJ, Dougan M, Reynolds KL. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2019 Nov 21. PMID: 31754069.
    Citations:    
  6. Seethapathy H, Zhao S, Chute DF, Zubiri L, Oppong Y, Strohbehn I, Cortazar FB, Leaf DE, Mooradian MJ, Villani AC, Sullivan RJ, Reynolds K, Sise ME. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. Clin J Am Soc Nephrol. 2019 12 06; 14(12):1692-1700. PMID: 31672794.
    Citations:    
  7. Guiney TE, Lopes MS, Kalra MK, Mooradian MJ, Neilan TG, Stone JR. Case 30-2019: A 65-Year-Old Woman with Lung Cancer and Chest Pain. N Engl J Med. 2019 Sep 26; 381(13):1268-1277. PMID: 31553841.
    Citations:    
  8. Criss SD, Mooradian MJ, Watson TR, Gainor JF, Reynolds KL, Kong CY. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States. JAMA Netw Open. 2019 Sep 04; 2(9):e1911952. PMID: 31553470.
    Citations:    
  9. Dubey D, David WS, Amato AA, Reynolds KL, Clement NF, Chute DF, Cohen JV, Lawrence DP, Mooradian MJ, Sullivan RJ, Guidon AC. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology. 2019 09 10; 93(11):e1093-e1103. PMID: 31405908.
    Citations:    
  10. Ameri AH, Mooradian MJ, Emerick KS, Park JC, Wirth LJ, Asgari MM, Tsao H, Lawrence D, Sullivan RJ, Demehri S. Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum. Br J Dermatol. 2019 Nov; 181(5):1095-1097. PMID: 31102460.
    Citations:    
  11. Molina GE, Allen IM, Hughes MS, Zubiri L, Lee H, Mooradian MJ, Reynolds KL, Dougan M, Chen ST. Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study. J Am Acad Dermatol. 2020 Mar; 82(3):743-746. PMID: 31349048.
    Citations:    
  12. Hughes MS, Zheng H, Zubiri L, Molina GE, Chen ST, Mooradian MJ, Allen IM, Reynolds KL, Dougan M. Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Med. 2019 Sep; 8(11):4986-4999. PMID: 31286682.
    Citations:    
  13. Criss SD, Mooradian MJ, Kong CY. Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer-In Reply. JAMA Oncol. 2019 07 01; 5(7):1066-1067. PMID: 31095247.
    Citations:    
  14. Digumarthy SR, Padole AM, Rastogi S, Price M, Mooradian MJ, Sequist LV, Kalra MK. Predicting malignant potential of subsolid nodules: can radiomics preempt longitudinal follow up CT? Cancer Imaging. 2019 Jun 10; 19(1):36. PMID: 31182167.
    Citations:    
  15. Mooradian MJ, Sullivan RJ. What to Do When Anti-PD-1 Therapy Fails in Patients With Melanoma. Oncology (Williston Park). 2019 Apr 15; 33(4):141-8. PMID: 30990567.
    Citations:    
  16. Lumish MA, Anderson MA, Rush PS, Fintelmann FJ, Duncan L, Sullivan RJ, Mooradian MJ. The metastatic dissemination of a squamous cell carcinoma arising from an epidermal cyst and subsequent failure to respond to programmed death 1 inhibition. JAAD Case Rep. 2019 Apr; 5(4):375-378. PMID: 31008173.
    Citations:    
  17. Criss SD, Mooradian MJ, Sheehan DF, Zubiri L, Lumish MA, Gainor JF, Reynolds KL, Kong CY. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System. JAMA Oncol. 2019 03 01; 5(3):358-365. PMID: 30543349.
    Citations:    
  18. Saab KR, Mooradian MJ, Wang DY, Chon J, Xia CY, Bialczak A, Abbate KT, Menzies AM, Johnson DB, Sullivan RJ, Shoushtari AN. Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy. Cancer. 2019 03 15; 125(6):884-891. PMID: 30521084.
    Citations:    Fields:    
  19. Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, Al-Rohil RN, Lee S, Voorhees AL, Ha L, McKee S, Norrell JT, Mehnert J, Puzanov I, Sosman JA, Chandra S, Gibney GT, Rapisuwon S, Eroglu Z, Sullivan R, Johnson DB. Clinical characterization of colitis arising from anti-PD-1 based therapy. Oncoimmunology. 2019; 8(1):e1524695. PMID: 30546965.
    Citations:    
  20. Zhang ML, Kem M, Mooradian MJ, Eliane JP, Huynh TG, Iafrate AJ, Gainor JF, Mino-Kenudson M. Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas. Mod Pathol. 2019 04; 32(4):511-523. PMID: 30367104.
    Citations:    Fields:    
  21. Mooradian MJ, Nasrallah M, Gainor JF, Reynolds KL, Cohen JV, Lawrence DP, Miloslavsky EM, Kohler MJ, Sullivan RJ, Schoenfeld SR. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience. Semin Arthritis Rheum. 2019 06; 48(6):1127-1132. PMID: 30409415.
    Citations:    Fields:    
  22. Dagogo-Jack I, Azzolli CG, Fintelmann F, Mino-Kenudson M, Farago AF, Gainor JF, Jiang G, Piotrowska Z, Heist RS, Lennes IT, Temel JS, Mooradian MJ, Lin JJ, Digumarthy SR, Batten JM, Robinson H, Nose V, Rivera M, Nardi V, Dias-Santagata D, Le LP, Sequist LV, Pitman M, Shepard JO, Shaw AT, Iafrate AJ, Lennerz JK. Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precis Oncol. 2018; 2018. PMID: 30370396.
    Citations:    
  23. Hirsch FR, Sequist LV, Gore I, Mooradian M, Simon G, Croft EF, DeVincenzo D, Munley J, Stein D, Freivogel K, Sifakis F, Bunn PA. Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP). Cancer. 2018 06 01; 124(11):2407-2414. PMID: 29579334.
    Citations:    Fields:    
  24. Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Giacomo AD, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P. Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124]. Eur J Cancer. 2018 04; 93:158. PMID: 29548533.
    Citations:    Fields:    
  25. Mooradian MJ, Gainor JF. Putting the brakes on CTLA-4 inhibition in lung cancer? Transl Lung Cancer Res. 2018 Feb; 7(Suppl 1):S35-S38. PMID: 29531902.
    Citations:    
  26. Mooradian MJ, Reuben A, Prieto PA, Hazar-Rethinam M, Frederick DT, Nadres B, Piris A, Juneja V, Cooper ZA, Sharpe AH, Corcoran RB, Flaherty KT, Lawrence DP, Wargo JA, Sullivan RJ. A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. Oncoimmunology. 2018; 7(5):e1423172. PMID: 29721378.
    Citations: 1     
  27. Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Di Giacomo A, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. Eur J Cancer. 2018 03; 91:116-124. PMID: 29360604.
    Citations: 1     Fields:    Translation:HumansCells
  28. Mooradian MJ, Piotrowska Z, Drapkin BJ, Dias-Santagata D, Marcoux N, Arnaoutakis K, Nagy RJ, Lanman R, Iafrate AJ, Farago AF, Mino-Kenudson M, Hata AN, Sequist LV. Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer-Transformed EGFR Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2017; 1. PMID: 31032471.
    Citations:    
  29. Mooradian MJ, Sullivan RJ. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics. Future Oncol. 2017 Aug; 13(18):1649-1663. PMID: 28776423.
    Citations: 1     Fields:    Translation:HumansAnimals
  30. Mooradian MJ, Gainor JF. ALK Fusion Detection in Circulating Free DNA: Finding an Important Needle in the Haystack. Oncologist. 2017 07; 22(7):759-761. PMID: 28642334.
    Citations:    Fields:    Translation:Humans
  31. Huynh TG, Morales-Oyarvide V, Campo MJ, Gainor JF, Bozkurtlar E, Uruga H, Zhao L, Gomez-Caraballo M, Hata AN, Mark EJ, Lanuti M, Engelman JA, Mino-Kenudson M. Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment. J Thorac Oncol. 2016 11; 11(11):1869-1878. PMID: 27568346.
    Citations: 14     Fields:    Translation:Humans
  32. Campo M, Gerber D, Gainor JF, Heist RS, Temel JS, Shaw AT, Fidias P, Muzikansky A, Engelman JA, Sequist LV. Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies. J Thorac Oncol. 2016 11; 11(11):2022-2026. PMID: 27553514.
    Citations: 7     Fields:    Translation:Humans
  33. Herzberg B, Campo MJ, Gainor JF. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Oncologist. 2017 01; 22(1):81-88. PMID: 27534574.
    Citations: 6     Fields:    Translation:HumansCells
  34. Campo M, Al-Halabi H, Khandekar M, Shaw AT, Sequist LV, Willers H. Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer. Oncologist. 2016 08; 21(8):964-73. PMID: 27354669.
    Citations: 2     Fields:    Translation:Humans
  35. Schram AM, Comstock P, Campo M, Gorovets D, Mullally A, Bodio K, Arnason J, Berliner N. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol. 2016 Feb; 172(3):412-9. PMID: 26537747.
    Citations: 8     Fields:    Translation:Humans
  36. Campo M, Berliner N. Hemophagocytic Lymphohistiocytosis in Adults. Hematol Oncol Clin North Am. 2015 Oct; 29(5):915-25. PMID: 26461151.
    Citations: 6     Fields:    Translation:Humans
  37. Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1):S1-63. PMID: 25535693.
    Citations: 24     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Mooradian's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (116)
Explore
_
Co-Authors (76)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.